Rallybio Market Capitalization from 2010 to 2024
| RLYB Stock | USD 1.02 0.03 3.03% |
Check Rallybio Corp financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Rallybio Corp's main balance sheet or income statement drivers, such as Tax Provision of 1.2 K, Net Interest Income of 6.1 M or Interest Income of 6.1 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.96. Rallybio financial statements analysis is a perfect complement when working with Rallybio Corp Valuation or Volatility modules.
Rallybio | Market Capitalization |
Latest Rallybio Corp's Market Capitalization Growth Pattern
Below is the plot of the Market Cap of Rallybio Corp over the last few years. It is Rallybio Corp's Market Cap historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Rallybio Corp's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 42.32 M | 10 Years Trend |
|
Market Cap |
| Timeline |
Rallybio Market Capitalization Regression Statistics
| Arithmetic Mean | 271,720,669 | |
| Geometric Mean | 255,312,773 | |
| Coefficient Of Variation | 28.07 | |
| Mean Deviation | 55,678,792 | |
| Median | 306,519,914 | |
| Standard Deviation | 76,279,102 | |
| Sample Variance | 5818.5T | |
| Range | 214.7M | |
| R-Value | (0.68) | |
| Mean Square Error | 3365.8T | |
| R-Squared | 0.46 | |
| Significance | 0.01 | |
| Slope | (11,604,151) | |
| Total Sum of Squares | 81459T |
Rallybio Market Capitalization History
About Rallybio Corp Financial Statements
Rallybio Corp stakeholders use historical fundamental indicators, such as Rallybio Corp's Market Capitalization, to determine how well the company is positioned to perform in the future. Although Rallybio Corp investors may analyze each financial statement separately, they are all interrelated. For example, changes in Rallybio Corp's assets and liabilities are reflected in the revenues and expenses on Rallybio Corp's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Rallybio Corp. Please read more on our technical analysis and fundamental analysis pages.
Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut. Rallybio Corporaton operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 45 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Rallybio Corp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Rallybio Corp's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Rallybio Corp Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Rallybio Corp Stock:Check out the analysis of Rallybio Corp Correlation against competitors. For information on how to trade Rallybio Stock refer to our How to Trade Rallybio Stock guide.You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Rallybio Corp. If investors know Rallybio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Rallybio Corp listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.57) | Revenue Per Share 0.014 | Return On Assets (0.39) | Return On Equity (0.67) |
The market value of Rallybio Corp is measured differently than its book value, which is the value of Rallybio that is recorded on the company's balance sheet. Investors also form their own opinion of Rallybio Corp's value that differs from its market value or its book value, called intrinsic value, which is Rallybio Corp's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Rallybio Corp's market value can be influenced by many factors that don't directly affect Rallybio Corp's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Rallybio Corp's value and its price as these two are different measures arrived at by different means. Investors typically determine if Rallybio Corp is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Rallybio Corp's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.